157 related articles for article (PubMed ID: 12094474)
21. [WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)].
Haferlach T; Schoch C
Dtsch Med Wochenschr; 2002 Mar; 127(9):447-50. PubMed ID: 11870559
[No Abstract] [Full Text] [Related]
22. Diagnostic flow cytometry in hematology: the leukemias.
Marti GE
Pathol Immunopathol Res; 1986; 5(3-5):416-36. PubMed ID: 3299350
[No Abstract] [Full Text] [Related]
23. Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
Kern W; Voskova D; Schnittger S; Schoch C; Hiddemann W; Haferlach T
Hematol J; 2004; 5(5):410-8. PubMed ID: 15448667
[TBL] [Abstract][Full Text] [Related]
24. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotyping of leukemia.
Campana D; Behm FG
J Immunol Methods; 2000 Sep; 243(1-2):59-75. PubMed ID: 10986407
[TBL] [Abstract][Full Text] [Related]
26. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellström-Lindberg E; Tefferi A; Bloomfield CD
Blood; 2009 Jul; 114(5):937-51. PubMed ID: 19357394
[TBL] [Abstract][Full Text] [Related]
27. Suspected myelodysplastic/myeloproliferative neoplasm in a feline leukemia virus-negative cat.
Weeden AL; Taylor KR; Terrell SP; Gallagher AE; Wamsley HL
Vet Clin Pathol; 2016 Dec; 45(4):584-593. PubMed ID: 27870069
[TBL] [Abstract][Full Text] [Related]
28. Expression of cytokine receptors on different myeloid leukemic cells.
Koubek K; Kumberová A; Starý J; Babusíková O; Klamová H; Filipec M
Neoplasma; 1998; 45(4):198-203. PubMed ID: 9890661
[TBL] [Abstract][Full Text] [Related]
29. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
[TBL] [Abstract][Full Text] [Related]
30. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Bruserud O; Ulvestad E
Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
[TBL] [Abstract][Full Text] [Related]
31. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
32. Myelopoiesis and myeloproliferative disorders.
Raskin RE
Vet Clin North Am Small Anim Pract; 1996 Sep; 26(5):1023-42. PubMed ID: 8863389
[TBL] [Abstract][Full Text] [Related]
33. Immunophenotyping of AML and MDS and detection of residual disease.
Sanz MA; Sempere A
Baillieres Clin Haematol; 1996 Mar; 9(1):35-55. PubMed ID: 8730550
[TBL] [Abstract][Full Text] [Related]
34. [The role of bone marrow cells immunophenotypic study by flow cytometry in diagnosing myelodysplastic syndrome].
Czyz A; Dworacki G; Komarnicki M
Postepy Hig Med Dosw (Online); 2008 Jul; 62():354-63. PubMed ID: 18688206
[TBL] [Abstract][Full Text] [Related]
35. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of minimal residual disease in leukemia.
Faderl S; Kantarjian HM; Talpaz M; Estrov Z
Int J Oncol; 2000 Dec; 17(6):1277-87. PubMed ID: 11078816
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometric analysis of cell-surface and intracellular antigens in the diagnosis of acute leukemia.
Paredes-Aguilera R; Romero-Guzman L; Lopez-Santiago N; Burbano-Ceron L; Camacho-Del Monte O; Nieto-Martinez S
Am J Hematol; 2001 Oct; 68(2):69-74. PubMed ID: 11559944
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
Drach J; Drach D; Glassl H; Gattringer C; Huber H
Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
[TBL] [Abstract][Full Text] [Related]
39. The new WHO nomenclature: introduction and myeloid neoplasms.
Rodak BF; Leclair SJ
Clin Lab Sci; 2002; 15(1):44-54. PubMed ID: 12778956
[No Abstract] [Full Text] [Related]
40. Minimal residual disease detection by flow cytometry: Can it serve as a predictor of future relapse?
Felgar RE
Leuk Res; 2001 May; 25(5):409-11. PubMed ID: 11301109
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
